Allianz Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-100
| Closed | -$21.6K | – | 2123 |
|
|
2024
Q1 | $21.6K | Sell |
100
-4,300
| -98% | -$1.01M | ﹤0.01% | 2028 |
|
|
2023
Q4 | $1.14M | Sell |
4,400
-800
| -15% | -$196K | ﹤0.01% | 1544 |
|
|
2023
Q3 | $1.34M | Sell |
5,200
-1,400
| -21% | -$374K | ﹤0.01% | 1604 |
|
|
2023
Q2 | $1.88M | Buy |
6,600
+300
| +5% | +$89.3K | ﹤0.01% | 1304 |
|
|
2023
Q1 | $1.75M | Sell |
6,300
-300
| -5% | -$83K | ﹤0.01% | 1435 |
|
|
2022
Q4 | $1.83M | Buy |
6,600
+6,500
| +6,500% | +$1.84M | ﹤0.01% | 1318 |
|
|
2022
Q3 | $27K | Hold |
100
| – | – | ﹤0.01% | 1788 |
|
|
2022
Q2 | $20K | Sell |
100
-1,200
| -92% | -$245K | ﹤0.01% | 2218 |
|
|
2022
Q1 | $274K | Buy |
+1,300
| New | +$283K | ﹤0.01% | 2237 |
|
|
2021
Q4 | – | Sell |
-2,700
| Closed | -$764K | – | 2551 |
|
|
2021
Q3 | $764K | Buy |
2,700
+100
| +4% | +$32.8K | ﹤0.01% | 2053 |
|
|
2021
Q2 | $900K | Buy |
2,600
+1,700
| +189% | +$515K | ﹤0.01% | 1785 |
|
|
2021
Q1 | $252K | Buy |
+900
| New | +$243K | ﹤0.01% | 2080 |
|
|
2020
Q3 | – | Sell |
-32,000
| Closed | -$8.56M | – | 1912 |
|
|
2020
Q2 | $8.56M | Sell |
32,000
-18,000
| -36% | -$5.41M | 0.01% | 962 |
|
|
2020
Q1 | $15.8M | Sell |
50,000
-48,900
| -49% | -$14.8M | 0.02% | 650 |
|
|
2019
Q4 | $29.3M | Buy |
98,900
+38,300
| +63% | +$10.6M | 0.03% | 622 |
|
|
2019
Q3 | $14.1M | Sell |
60,600
-400
| -0.7% | -$93.1K | 0.01% | 934 |
|
|
2019
Q2 | $14.3M | Buy |
61,000
+19,900
| +48% | +$4.59M | 0.01% | 987 |
|
|
2019
Q1 | $9.71M | Sell |
41,100
-74,000
| -64% | -$23.3M | 0.01% | 1163 |
|
|
2018
Q4 | $34.6M | Sell |
115,100
-25,500
| -18% | -$8.14M | 0.04% | 483 |
|
|
2018
Q3 | $49.7M | Sell |
140,600
-22,300
| -14% | -$7.68M | 0.05% | 434 |
|
|
2018
Q2 | $47.3M | Buy |
162,900
+9,500
| +6% | +$2.67M | 0.05% | 434 |
|
|
2018
Q1 | $42M | Sell |
153,400
-237,600
| -61% | -$73.8M | 0.04% | 507 |
|
|
2017
Q4 | $125M | Buy |
391,000
+47,100
| +14% | +$15.1M | 0.1% | 248 |
|
|
2017
Q3 | $108M | Buy |
343,900
+101,700
| +42% | +$30.1M | 0.09% | 258 |
|
|
2017
Q2 | $65.7M | Sell |
242,200
-48,000
| -17% | -$12.7M | 0.06% | 360 |
|
|
2017
Q1 | $79.3M | Sell |
290,200
-312,500
| -52% | -$88.4M | 0.08% | 301 |
|
|
2016
Q4 | $171M | Buy |
602,700
+256,800
| +74% | +$76.1M | 0.15% | 146 |
|
|
2016
Q3 | $108M | Buy |
345,900
+34,400
| +11% | +$10.2M | 0.11% | 209 |
|
|
2016
Q2 | $75.3M | Buy |
311,500
+177,800
| +133% | +$46.9M | 0.08% | 276 |
|
|
2016
Q1 | $34.8M | Buy |
133,700
+37,700
| +39% | +$9.96M | 0.04% | 506 |
|
|
2015
Q4 | $29.4M | Buy |
96,000
+28,600
| +42% | +$8.22M | 0.03% | 584 |
|
|
2015
Q3 | $19.7M | Sell |
67,400
-46,500
| -41% | -$15.4M | 0.02% | 710 |
|
|
2015
Q2 | $46M | Buy |
113,900
+22,400
| +24% | +$8.99M | 0.05% | 462 |
|
|
2015
Q1 | $38.6M | Sell |
91,500
-33,300
| -27% | -$13.1M | 0.04% | 462 |
|
|
2014
Q4 | $42.4M | Buy |
124,800
+76,300
| +157% | +$24.7M | 0.05% | 429 |
|
|
2014
Q3 | $16M | Buy |
+48,500
| New | +$16M | 0.02% | 699 |
|
Other funds holding BIIB
VCM
VPM
Allianz Asset Management's BIIB Position: Q1 2026 in Review
Allianz Asset Management reduced its Biogen (BIIB) stake by 28% in Q1 2026, selling an estimated $12.8M and leaving 178,049 shares worth $32.6M. The position accounts for 0.03% of the portfolio, ranked #459.
Allianz Asset Management first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $409M in Q2 2015. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Allianz Asset Management held 178,049 shares of Biogen worth $32.6M as of Q1 2026.
- Allianz Asset Management sold 69,673 Biogen shares in Q1 2026, an estimated $12.8M.
- Biogen made up 0.03% of Allianz Asset Management's portfolio in Q1 2026, its #459 holding.
- Allianz Asset Management first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
- Allianz Asset Management's Biogen position peaked at $409M in Q2 2015.
- 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.